Quantitative Oncologic PET-MR

定量肿瘤学 PET-MR

• 批准号: 10605305
• 负责人: Georges El Fakhri
• 金额: $ 44.82万
• 依托单位: MASSACHUSETTS GENERAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-05-01 至 2024-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10605305
• 关键词: 3-Dimensional; Address; Aftercare; Anatomy; Area; Bone Tissue; Cancer Control; Cells; Characteristics; Clinical; Clinical Trials; Compensation; Data; Detection; Diameter; Discrimination; Disease; Disease model; Dose; Edema; Effectiveness; Excision; External Beam Radiation Therapy; Failure; Future; Goals; Guidelines; Histologic; Histopathology; Image; Image Enhancement; Infiltration; Inflammation; Judgment; Knowledge; Left; Lipids; Magnetic Resonance Imaging; Malignant Neoplasms; Maps; Measures; Methods; Microscopic; Mitotic; Motion; Necrosis; Normal tissue morphology; Operative Surgical Procedures; Pathologic; Pathologist; Patients; Phase; Physicians; Physiologic pulse; Population; Positron-Emission Tomography; Printing; Process; Progression-Free Survivals; Radiation Dose Unit; Radiation Oncologist; Radiation therapy; Recurrence; Resected; Resistance; Resolution; Risk; Risk Factors; Sampling; Soft tissue sarcoma; Targeted Radiotherapy; Treatment Effectiveness; Treatment outcome; Tumor Tissue; Tumor Volume; Validation; Visualization; Voting; Water; anatomic imaging; biological heterogeneity; cancer imaging; cancer radiation therapy; fluorodeoxyglucose; fluorodeoxyglucose positron emission tomography; fractionated radiation; high risk; imaging biomarker; imaging modality; improved; indexing; molecular imaging; multiparametric imaging; neoplastic cell; novel; phase 1 study; predictive modeling; radio frequency; radiologist; respiratory; sarcoma; side effect; spectroscopic imaging; synergism; tool; treatment planning; treatment response; tumor; virtual; 3-Dimensional; Address; Aftercare; Anatomy; Area; Bone Tissue; Cancer Control; Cells; Characteristics; Clinical; Clinical Trials; Compensation; Data; Detection; Diameter; Discrimination; Disease; Disease model; Dose; Edema; Effectiveness; Excision; External Beam Radiation Therapy; Failure; Future; Goals; Guidelines; Histologic; Histopathology; Image; Image Enhancement; Infiltration; Inflammation; Judgment; Knowledge; Left; Lipids; Magnetic Resonance Imaging; Malignant Neoplasms; Maps; Measures; Methods; Microscopic; Mitotic; Motion; Necrosis; Normal tissue morphology; Operative Surgical Procedures; Pathologic; Pathologist; Patients; Phase; Physicians; Physiologic pulse; Population; Positron-Emission Tomography; Printing; Process; Progression-Free Survivals; Radiation Dose Unit; Radiation Oncologist; Radiation therapy; Recurrence; Resected; Resistance; Resolution; Risk; Risk Factors; Sampling; Soft tissue sarcoma; Targeted Radiotherapy; Treatment Effectiveness; Treatment outcome; Tumor Tissue; Tumor Volume; Validation; Visualization; Voting; Water; anatomic imaging; biological heterogeneity; cancer imaging; cancer radiation therapy; fluorodeoxyglucose; fluorodeoxyglucose positron emission tomography; fractionated radiation; high risk; imaging biomarker; imaging modality; improved; indexing; molecular imaging; multiparametric imaging; neoplastic cell; novel; phase 1 study; predictive modeling; radio frequency; radiologist; respiratory; sarcoma; side effect; spectroscopic imaging; synergism; tool; treatment planning; treatment response; tumor; virtual

PROJECT SUMMARY The overall goal of this competing renewal application remains focused on developing and leveraging quantitative molecular imaging biomarkers that take advantage of a synergy between PET and MR imaging to provide significantly improved guidance for cancer radiation therapy (RT) in sarcomas. Traditionally, definition of the radiotherapy target volume utilizes CT and (sometimes) MR images to delineate visible gross tumor volume (GTV) which is expanded by certain margins to account for microscopic disease according to clinical guidelines, forming the clinical target volume (CTV). The standard T1/T2 weighted MR images are unable to distinguish tumor infiltration from inflammation and therefore inclusion of edema into the CTV is left to the physician's judgment. For patients unable to have resection, definitive RT results in local control of only 40 to 75% with the failures occurring primarily within the gross tumor. Standard anatomic imaging does not allow identification of areas at risk of local failure. We hypothesize that multiparametric PET/MR imaging will help to identify potential areas of resistant cell populations within the tumor in order to prescribe the higher dose to these areas to increase treatment effectiveness.

项目摘要 该竞争性更新应用程序的总体目标仍然专注于开发和利用 定量分子成像生物标志物，利用PET和MR成像之间的协同作用 在肉瘤中提供了明显改善癌症放射疗法（RT）的指导。传统上，定义 放射疗法的目标体积利用CT和（有时）MR图像来描述可见的总肿瘤 通过某些边缘扩大的体积（GTV），根据临床疾病考虑微观疾病 指南，形成临床目标体积（CTV）。标准T1/T2加权MR图像无法 将肿瘤浸润与炎症区分开，因此将水肿纳入CTV 医师的判断。 对于无法切除的患者，确定的RT导致局部控制仅40％至75％ 主要发生在总肿瘤内。标准解剖成像不允许识别 局部失败的风险。我们假设多参数宠物/MR成像将有助于确定 肿瘤内的抗性细胞群体，以便开出更高的剂量以增加这些区域 治疗效率。